Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clyde Markowitz

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Expert Opinion on Emerging Drugs|December 2, 2004
Development of interferon-beta as a therapy for multiple sclerosisClyde Markowitz
Continuum (Minneapolis, Minn.)|July 20, 2012
Symptomatic therapy of multiple sclerosisClyde Markowitz
JAMA Neurology|September 23, 2018
Deciding on the Best Multiple Sclerosis Therapy: Tough ChoicesJoseph R Berger, Clyde Markowitz
CNS Drugs|March 3, 2005
US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profilesSteven L Galetta, Clyde Markowitz
Archives of Internal Medicine|October 24, 2002
Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic reviewSteven L Galetta, Clyde Markowitz, Andrew G Lee
The American Journal of Medicine|January 4, 2014
Novel therapeutics in multiple sclerosis management: clinical applicationsThomas Leist, Samuel F Hunter, Daniel Kantor, et al.
Neurology. Clinical Practice|January 11, 2024
A Proposed Approach to Screening and Surveillance Labs for Patients With Multiple Sclerosis on Anti-CD20 TherapyStephanie Gandelman, Kerry A Lenzi, Clyde Markowitz, et al.
International Journal of MS Care|January 24, 2014
The Combined Effect of Nursing Support and Adverse Event Mitigation on Adherence to Interferon Beta-1b Therapy in Early Multiple Sclerosis: The START StudySuhayl Dhib-Jalbut, Clyde Markowitz, Payal Patel, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 9, 2011
A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial designEdward Fox, Daniel Wynn, Stanley Cohan, et al.
Journal of the Neurological Sciences|March 3, 2015
Analysis of the treatment of neuromyelitis opticaJose Torres, Amy Pruitt, Laura Balcer, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Expert Opinion on Emerging Drugs|December 2, 2004
Development of interferon-beta as a therapy for multiple sclerosisClyde Markowitz
Continuum (Minneapolis, Minn.)|July 20, 2012
Symptomatic therapy of multiple sclerosisClyde Markowitz
JAMA Neurology|September 23, 2018
Deciding on the Best Multiple Sclerosis Therapy: Tough ChoicesJoseph R Berger, Clyde Markowitz
CNS Drugs|March 3, 2005
US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profilesSteven L Galetta, Clyde Markowitz
Archives of Internal Medicine|October 24, 2002
Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic reviewSteven L Galetta, Clyde Markowitz, Andrew G Lee
The American Journal of Medicine|January 4, 2014
Novel therapeutics in multiple sclerosis management: clinical applicationsThomas Leist, Samuel F Hunter, Daniel Kantor, et al.
Neurology. Clinical Practice|January 11, 2024
A Proposed Approach to Screening and Surveillance Labs for Patients With Multiple Sclerosis on Anti-CD20 TherapyStephanie Gandelman, Kerry A Lenzi, Clyde Markowitz, et al.
International Journal of MS Care|January 24, 2014
The Combined Effect of Nursing Support and Adverse Event Mitigation on Adherence to Interferon Beta-1b Therapy in Early Multiple Sclerosis: The START StudySuhayl Dhib-Jalbut, Clyde Markowitz, Payal Patel, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 9, 2011
A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial designEdward Fox, Daniel Wynn, Stanley Cohan, et al.
Journal of the Neurological Sciences|March 3, 2015
Analysis of the treatment of neuromyelitis opticaJose Torres, Amy Pruitt, Laura Balcer, et al.
Pageof 3